"Research conducted by scientists and surgeons from both institutions demonstrated that MDRNA's UsiRNA targeting human survivin and delivered via DiLA2 liposomes achieved up to 90%target knockdown in a mouse model of orthotopic bladder cancer."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.